```markdown
---
application_number: 216686Orig1s000
letter_type: Complete Response
submission_type: NDA 216686
applicant: Spes Pharmaceuticals Inc.
applicant_contact:
  name: Jianwei Yu, PhD
  title: President, CEO and CSO
  address: 675 US Highway 1, Suite 118, North Brunswick, NJ 08902
drug_name: Fosaprepitant Injection
dosage_form: 150 mg/50 mL (3 mg/mL)
submission_dates:
  application_date: 2021-12-22
  received_date: 2021-12-23
letter_date: 2022-10-19
signatory:
  name: Joyce Korvick, MD, MPH
  role: Deputy Director for Safety
  division: Division of Gastroenterology
  office: Office of Immunology and Inflammation, Office of New Drugs
  center: Center for Drug Evaluation and Research
contact:
  name: Maureen Dewey
  title: Senior Regulatory Project Manager
  phone: (301) 796-0845
facilities_inspected:
  - name: Pharmaceutics International, Inc.
    FEI: 3006503102
  - name: Pharmaceutics International, Inc.
    FEI: 1000513101
electronic_signature:
  signer: JOYCE A KORVICK
  timestamp: 2022-10-19T13:03:26
---

## Critical Data

| Field                         | Information                                               |
|------------------------------|-----------------------------------------------------------|
| Application Number           | 216686Orig1s000                                           |
| Submission Type              | NDA 216686                                                |
| Letter Type                  | Complete Response                                         |
| Applicant                    | Spes Pharmaceuticals Inc.                                 |
| Contact Person               | Jianwei Yu, PhD                                           |
| Contact Title                | President, CEO and CSO                                    |
| Applicant Address            | 675 US Highway 1, Suite 118, North Brunswick, NJ 08902   |
| Drug Name                    | Fosaprepitant Injection                                   |
| Dosage Form                  | 150 mg/50 mL (3 mg/mL)                                    |
| Application Date             | December 22, 2021                                         |
| Received Date                | December 23, 2021                                         |
| Letter Date                  | October 19, 2022                                          |
| FDA Signatory                | Joyce Korvick, MD, MPH                                    |
| Regulatory Contact at FDA    | Maureen Dewey, (301) 796-0845                             |
| Facilities Inspected         | Pharmaceutics International, Inc. (FEI 3006503102, 1000513101) |
| Electronic Signature Time    | 2022-10-19 01:03:26 PM                                    |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPLICATION NUMBER: 216686Orig1s000  
## OTHER ACTION LETTERS  

### NDA 216686  
### COMPLETE RESPONSE  

Spes Pharmaceuticals Inc.  
Attention: Jianwei Yu, PhD  
President, CEO and CSO  
675 US Highway 1, Suite 118  
North Brunswick, NJ 08902  

Dear Dr. Yu,

Please refer to your new drug application (NDA) dated December 22, 2021, received December 23, 2021, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA), for fosaprepitant injection, 150 mg/50 mL (3 mg/mL).

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## PRODUCT QUALITY / FACILITY INSPECTIONS

1. During a recent inspection of the Pharmaceutics International, Inc. (FEI 3006503102) manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

2. During a recent inspection of the Pharmaceutics International, Inc. (FEI 1000513101) manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION

When you respond to the above deficiencies, submit draft labeling that is responsive to our electronic communications dated August 23, 2022 (Prescribing Information) and August 24, 2022 (Patient Package Insert).

Prior to resubmitting the labeling:

- Use the SRPI checklist to correct any formatting errors to ensure conformance with the format items in regulations and guidances.
- Submit updated content of labeling [21 CFR: 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at [FDA SPL](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm).
- Provide a highlighted or marked-up copy that shows all changes, as well as a clean Word version.
  - The marked-up copy should include annotations that support any proposed changes.

Your proposed Prescribing Information (PI) must conform to the content and format regulations found at 21 CFR 201.56(a) and (d) and 201.57.

Labeling review resources are available at:

- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)
- [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule)

These include:

- The Final Rule (Physician Labeling Rule) on content and format of the PI for human drug and biological products
- The Final Rule (Pregnancy and Lactation Labeling Rule) on content and format of information in the PI on pregnancy, lactation, and females and males of reproductive potential
- Regulations and related guidance documents
- A sample tool illustrating the format for Highlights and Contents
- The Selected Requirements for Prescribing Information (SRPI) checklist of important format items from labeling regulations and guidances
- FDA’s established pharmacologic class (EPC) text phrases for inclusion in the Highlights Indications and Usage heading
- Additional resources for the PI, patient labeling, and carton/container labeling

---

## CARTON AND CONTAINER LABELING

When you respond to the above deficiencies:

- Submit draft carton and container labeling that is responsive to our electronic communication dated August 23, 2022.
- Revise the container label as shown in Table 1.

---

## CLINICAL SAFETY DATA

- Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.
- Present tabulations of the new safety data combined with the original application data.
- Include tables that compare frequencies of adverse events in the original application with the re-tabulated frequencies described above.
- For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
- Present a re-tabulation of the reasons for premature trial discontinuation by incorporating dropouts from newly completed trials. Describe any new trends or patterns identified.
- Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial because of an adverse event. Also provide narrative summaries for serious adverse events.
- Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.
- Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).
- Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.
- Provide English translations of current approved foreign labeling not previously submitted.

---

## OTHER

Within one year after the date of this letter, you are required to:

- Resubmit or take other actions available under 21 CFR 314.110.  
- If no action is taken, your lack of response may be considered a request to withdraw the application under 21 CFR 314.65.  
- You may request an extension of time in which to resubmit the application.

A resubmission must:

- Fully address all the deficiencies listed in this letter
- Be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter
- Clearly state that you consider this resubmission a complete response to the deficiencies outlined

A partial response to this letter:

- Will not be processed as a resubmission
- Will not start a new review cycle

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance:  
“Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products.”

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call:

**Maureen Dewey**  
Senior Regulatory Project Manager  
(301) 796-0845

Sincerely,  
{See appended electronic signature page}

**Joyce Korvick, MD, MPH**  
Deputy Director for Safety  
Division of Gastroenterology  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

---

/s/  
**JOYCE A KORVICK**  
10/19/2022 01:03:26 PM
```